1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsLung Cancer Research Program Translational Research Award (HT942526LCRPTRA) is sponsored by Department of Defense (DoD). Supports advanced translational research that will foster the transformation of promising ideas in lung cancer into clinical applications.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DoW Lung Cancer Translational Research Award Dept.
of the Army -- USAMRAA Document Type:Grants Notice Funding Opportunity Number:HT942526LCRPTRA Funding Opportunity Title:DoW Lung Cancer Translational Research Award Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Science and Technology and other Research and Development Expected Number of Awards:6 Assistance Listings:12.
420 -- Military Medical Research and Development Cost Sharing or Matching Requirement:No Last Updated Date:May 06, 2026 Original Closing Date for Applications:Sep 02, 2026 Current Closing Date for Applications:Sep 02, 2026 Archive Date:Oct 02, 2026 Estimated Total Program Funding:$ 9,100,000 Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: ## Additional Information Agency Name:Dept.
of the Army -- USAMRAA Description:**Summary:** The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.
**Distinctive Features:** This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions. Link to Additional Information:[](https://www. grants.
gov/search-results-detail/362250) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: ## Similar Opportunities (identified by AI)
According to the current listing, eligibility includes: Investigators at eligible organizations (preliminary lung cancer relevant data required). Confirm the full requirements in the official notice before applying.
The published deadline was June 23, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Lung Cancer Research Program Translational Research Award (HT942526LCRPTRA) is funded by Department of Defense (DoD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe Department's FY26 SBIR/STTR Release 3 opened June 24 with roughly 37 topics across DARPA, the Navy, the Air Force, and the defense components, all closing July 22. The compressed four-week window is unforgiving, but the bigger mistake founders make is treating every component the same. Here is how to read the release, the eligibility rules that disqualify good companies, and why the component you target matters more than the topic you pick.
Read article